Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[123I]ß-CIT SPECT Imaging in Parkinsonism
NCT00132626Phase 2Completed
- Sponsor
- Institute for Neurodegenerative Disorders
- Start
- Sep 1992
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of [123I]beta-CIT in Parkinson's disease (PD) and parkinsonian syndrome, sponsored by Institute for Neurodegenerative Disorders. Primary endpoint: Dopamine transporter density (CIT uptake) at 24 hours. Started Sep 1992; status: completed.
02
Drugs
[123I]beta-CIT
03
Conditions
Parkinson's disease (PD)parkinsonian syndrome
Beyond the preview
Go deeper on NCT00132626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132626.